How to improve exposure of tumor cells to drugs - Promoter drugs increase tumor uptake and penetration of effector drugs

Advanced Drug Delivery Reviews

Volumn 64, Issue 1, 2012, Pages 53-68

  Marcucci, Fabrizio ^a,b   Corti, Angelo ^c  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Hepatology Association of Calabria   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Barrier function of tumor vessels; Future investigations in promoter drug research; Promoter drug research and development; Stromal barriers; Tumor architecture and composition; Tumor blood flow; Tumor cell killing; Tumor uptake and distribution of drugs

Indexed keywords

DRUG RESEARCH; FUTURE INVESTIGATIONS IN PROMOTER DRUG RESEARCH; STROMAL BARRIERS; TUMOR CELL KILLING; TUMOR UPTAKE AND DISTRIBUTION OF DRUGS; TUMOR VESSELS;

HEMODYNAMICS; RESEARCH;

TUMORS;

ALPHA INTERFERON; ANGIOTENSIN II; ARGININE; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; BOTULINUM TOXIN; BRADYKININ B2 RECEPTOR AGONIST; CISPLATIN; COLLAGENASE; DOXORUBICIN; ENDOTHELIN RECEPTOR ANTAGONIST; HISTAMINE; HYALURONIDASE; HYDROXYUREA; INTERLEUKIN 2; INTETUMUMAB; LOBRADIMIL; LOSARTAN; MONOCLONAL ANTIBODY DC101; NICOTINAMIDE; PACLITAXEL; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROSTAGLANDIN E2; REGULATOR OF G PROTEIN SIGNALING 5; RGS PROTEIN; SELENIUM; SONIC HEDGEHOG PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BODY TEMPERATURE; CANCER MORPHOLOGY; COLORECTAL CARCINOMA; DRUG EXPOSURE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG UPTAKE; HUMAN; INTRACELLULAR TRANSPORT; MELANOMA; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOLID TUMOR; TRANSCYTOSIS; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; REGIONAL BLOOD FLOW;

EID: 84858447459     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.09.007     Document Type: Review

References (174)

1. Minchinton A.I., Tannock I.F. Drug penetration in solid tumors. Nat. Rev. Cancer 2006, 6(2006):583-592.
2. Padera T.P., Stoll B.R., Tooredman J.B., Capen D., di Tomaso E., Jain R.K. Pathology: cancer cells compress intratumour vessels. Nature 2004, 427:695.
3. Hirst D.G., Denekamp J. Tumour cell proliferation in relation to the vasculature. Cell Tissue Kinet. 1979, 12:31-42.
4. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res. 1988, 48:2641-2658.
5. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
6. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., McDonald D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 2000, 156:1363-1380.
7. Leu A.J., Berk D.A., Lymboussaki A., Alitalo K., Jain R.K. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000, 60:4324-4327.
8. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 2010, 21:797-802.
9. Heldin C.-H., Rubin K., Pietras K., Östman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4:806-813.
10. Netti P.A., Berk D.A., Swartz M.A., Grodzinsky A.J., Jain R.K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000, 60:2497-2503.
11. Boucher Y., Kirkwood J.M., Opacic D., Desantis M., Jain R.K. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res. 1991, 51:6691-6694.
12. Gutmann R., Leunig M., Feyh J., Goetz A.E., Messmer K., Kastenbauer E., Jain R.K. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res. 1992, 52:1993-1995.
13. Stohrer M., Boucher Y., Stangassinger M., Jain R.K. Oncotic pressure in solid tumors is elevated. Cancer Res. 2000, 60:4251-4255.
14. Choi J., Credit K., Henderson K., Deverkadra R., He Z., Wiig H., Vanpelt H., Flessner M.F. Intraperitoneal immunotherapy for metastatic ovarian carcinoma: resistance of intratumoral collagen to antibody penetration. Clin. Cancer Res. 2006, 12:1906-1913.
15. de Lange Davies C., Berk D.A., Pluen A., Jain R.K. Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br. J. Cancer 2002, 86:1639-1644.
16. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:4607-4612.
17. Pluen A., Boucher Y., Ramanujan S., McKee T.D., Gohongi T., di Tomaso E., Brown E.B., Izumi Y., Campbell R.B., Berk D.A., Jain R.K. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:4628-4633.
18. Milosevic M.F., Fyles A.W., Wong R., Pintilie M., Kavanagh M.-C., Levin W., Manchul L.A., Keane T.J., Hill R.P. Interstitial fluid pressure in cervical carcinoma - within tumor heterogeneity, and relation to oxygen tension. Cancer 1998, 82:2418-2426.
19. Williamson M.J., Silva M.D., Terkelsen J., Robertson R., Yu L., Xia C., Hatsis P., Bannerman B., Babcock T., Cao Y., Kupperman E. The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Mol. Cancer Ther. 2009, 8:3234-3243.
20. Marcucci F., Lefoulon F. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discov. Today 2004, 9:219-228.
21. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., Catane R., Kieback D.G., Tomczak P., Ackland S.P., Orlandi F., Mellars L., Alland L., Tendler C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004, 15:440-449. CAELYX Breast Cancer Study Group.
22. Sim H., Bibee K., Wickline S., D Pharmacokinetic modeling of tumor bioluminescence implicates efflux, and not influx, as the bigger hurdle in cancer drug therapy. Cancer Res. 2011, 71:686-692.
23. Thurber G.M., Schmidt M.M., Wittrup K.D. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev. 2008, 60:1421-1434.
24. Juweid M., Neumann R., Paik C., Perez-Bacete M.J., Sato J., van Osdol W., Weinstein J.W. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992, 52:5144-5153.
25. Rudnick S.I., Lou J., Shaller C.C., Tang Y., Klein-Szanto A.J., Weiner L.M., Marks J.D., Adams G.P. Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors. Cancer Res. 2011, 71:2250-2259.
26. Ackerman M.E., Pawlowski D., Wittrup K.D. Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol. Cancer Ther. 2008, 7:2233-2240.
27. West G.W., Weichselbaum R., Little J.B. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res. 1980, 40:3665-3668.
28. Tunggal J.K., Cowan D.S.M., Shaikh H., Tannock I.F. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin. Cancer Res. 1999, 5:1583-1586.
29. Tannock I.F., Lee C.M., Tunggal J.K., Cowan D.S.M., Egorin M.J. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin. Cancer Res. 2002, 8:878-884.
30. Hicks K.O., Pruijn F.B., Secomb T.W., Hay M.P., Hsu R., Brown J.M., Denny W.A., Dewhirst M.W., Wilson W.R. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J. Natl. Cancer Inst. 2006, 98:1118-1128.
31. Grantab R., Sivananthan S., Tannock I.F. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res. 2006, 66:1033-1039.
32. Patel K.J., Tannock I.F. The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer. 2009, 9:356.
33. Huxham L.A., Kyle A.H., Baker J.H.E., Nykilchuk L.K., Minchinton A.I. Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res. 2004, 64:6537-6541.
34. Primeau A.J., Rendon A., Hedley D., Lilge L., Tannock I.F. The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin. Cancer Res. 2005, 11:8782-8788.
35. Lankelma J., Dekker H., Luque R.F., Luykx S., Hoekman K., van der Valk P., van Diest P.J., Pinedo H.M. Doxorubicin gradients in human breast cancer. Clin. Cancer Res. 1999, 5:1703-1707.
36. Trédan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99:1441-1454.
37. Dreher M.R., Liu W., Michelich C.R., Dewhirst M.W., Yuan F., Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst. 2006, 98:335-344.
38. Moulder J.E., Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev. 1987, 5:313-341.
39. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
40. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
41. Thurber G.M., Wittrup K.D. Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res. 2008, 68:3334-3341.
42. Kubetzko S., Balic E., Waibel R., Zangmeister-Wittke U., Plückthun A. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: Effects on tumor targeting. J. Biol. Chem. 2006, 281:35186-35201.
43. Fidarova E.F., El-Emir E., Boxer G.M., Qureshi U., Dearling J.L.J., Robson M.P., Begent R.H.J., Trott K.R., Pedley R.B. Microdistribution of targeted, fluorescently labeled anti-carcinoembryonic antigen antibody in metastatic colorectal cancer: implications for radioimmunotherapy. Clin. Cancer Res. 2008, 14:2639-2646.
44. El Emir E., Qureshi U., Dearling J.L.J., Boxer G.M., Clatworthy I., Folarin A.A., Robson M.P., Nagl S., Konerding M.A., Padley R.B. Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas. Cancer Res. 2007, 67:11896-11905.
45. Lee C.M., Tannock I.F. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer. 2010, 10:255.
46. v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin. Cancer Res. 2007, 13:2128-2136. in association with the Biotherapy Development Association.
47. O'Dwyer P.J., Manola J., Valone F.H., Ryan L.M., Hines J.D., Wadler S., Haller D.G., Arbuck S.G., Weiner L.M., Mayer R.J., Benson A.B. Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonoacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule-an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J. Clin. Oncol. 2001, 19:2413-2421.
48. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., Oldfield E.H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:2076-2080.
49. Suzuki M., Hon K., Abe I., Saito S., Sato H. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J. Natl. Cancer Inst. 1981, 67:663-669.
50. Abe I., Hori K., Saito S., Tanda S., Li Y., Suzuki M. Increased intratumor concentration of fluorescein-isothiocyanate-labeled neocarzinostatin in rats under angiotensin-induced hypertension. Jpn. J. Cancer Res. 1988, 79:874-879.
51. Li C.J., Miyamoto Y., Kojima Y., Maeda H. Augmentation of tumor delivery macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer 1993, 67:975-9801.
52. Hori K., Thang Q., Saito S., Tanda S., Li H., Suzuki M. Microvascular mechanism of change in tumor blood flow due to angiotensin II epinephrine, and methoxamine: a functional morphometric study. Cancer Res. 1993, 53:5528-5534.
53. Netti P.A., Baxter L.T., Boucher Y., Skalak R., Jain R.K. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res. 1995, 55:5451-5458.
54. Netti P.A., Hamberg L.M., Babich J.W., Kierstead D., Graham W., Hunter G.J., Wolf G.L., Fischman A., Boucher Y., Jain R.K. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:3137-3142.
55. Nagamitsu A., Greish K., Maeda H. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn. J. Clin. Oncol. 2009, 39:756-766.
56. Sonveaux P., Dessy C., Martinive P., Havaux X., Jordan B.F., Gallez B., Grégoire V., Balligand J.-L., Feron O. Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res. 2004, 64:3209-3214.
57. Buckanovich R.J., Facciabene A., Kim S., Benencia F., Sasaroli D., Balint K., Katsaros D., O'Brien-Jenkins A., Gimotty P.A., Coukos G. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 2008, 14:28-36.
58. Said N., Smith S., Sanchez-Carbayo M., Theodorescu D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J. Clin. Invest. 2011, 121:132-147.
59. Lee I., Boucher Y., Jain R.K. Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. Cancer Res. 1992, 52:3237-3240.
60. Emerich D.F., Dean R.L., Snodgrass P., Lafreniere D., Agostino M., Wiens T., Xiong H., Hasler B., Marsh J., Pink M., Kim B.S., Perdomo B., Bartus R.T. Bradykinin modulation of tumor vasculature: II. Activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. J. Pharmacol. Exp. Ther. 2001, 296:632-641.
61. Emerich D.F., Snodgrass P., Dean R., Lafreniere D., Agostino M., Wiens T., Xiong H., Hasler B., Marsh J., Pink M., Kim B.-S., Bartus R. Bradykinin modulation of tumor vasculature: I. Activation of B2 receptors increases delivery of chemotherapeutic agents into solid peripheral tumors, enhancing their efficacy. J. Pharmacol. Exp. Ther. 2001, 296:623-631.
62. Thomas H.D., Lind M.J., Ford J., Bleehen N., Calvert A.H., Boddy A.V. Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. Cancer Chemother. Pharmacol. 2000, 45:284.
63. Wu J., Akaike T., Hayashida K., Miyamoto Y., Nakagawa T., Miyakawa K., Müller-Esterl W., Maeda H. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int. J. Cancer 2002, 98:29.
64. Warren K., Gervais A., Aikin A., Egorin M., Balis F.M. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors. Cancer Chemother. Pharmacol. 2004, 54:206-212.
65. Sarin H., Kanevsky A.S., Fung S.H., Butman J.A., Cox R.W., Glen D., Reynolds R., Auh S. Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. J. Transl. Med. 2009, 7:33.
66. Ansiaux R., Baudelet C., Cron G.O., Segers J., Dessy C., Martinive P., De Wever J., Verrax J., Wauthier V., Beghein N., Grégoire V., Buc Calderon P., Feron O., Gallez B. Botulinum toxin potentiates cancer radiotherapy and chemotherapy. Clin. Cancer Res. 2006, 12:1276-1283.
67. Sen A., Capitano M.L., Spernyak J.A., JT Schueckler, Thomas S., Singh A.K., Evans S.S., Hylander B.L., Repasky E.A. Mild elevation of body temperature reduces tumor interstitial fluid pressure and hypoxia and enhances efficacy of radiotherapy in murine tumor models. Cancer Res. 2011, 71:3872-3880.
68. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Med. 2001, 7:987-989.
69. O'Connor J.P.B., Carano R.A.D., Clamp A.R., Ross J., Ho C.C.K., Jackson A., Parker G.J.M., Rose C.J., Peale F.V., Friesenhahn M., Mitchell C.L., Watson Y., Roberts C., Hope L., Cheung S., Bou Reslan H., Go M.A.T., Pacheco G.J., Wu X., Cao T.C., Ross S., Buonaccorsi G.A., Davies K., Hasan J., Thornton P., del Puerto O., Ferrara N., van Bruggen N., Jayson G.C. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin. Cancer Res. 2009, 15:6674-6682.
70. Wildiers H., Guetens G., De Boeck G., Verbeken E., Landuyt B., Landuyt W., de Bruijn E.S., van Oosterom A.T. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer 2003, 88(2003):1979-1986.
71. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vscular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 64:3731-3736.
72. Nakahara T., Norberg S.M., Shalinsky D.R., Hu-Lowe D.D., McDonald D.M. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 2006, 66:1434-1445.
73. Gerber H.-P., Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005, 65:671-680.
74. Huber P.E., Bischof M., Jenne J., Heiland S., Peschke P., Saffrich R., Gröne H.-J., Debus J., Lipson K.E., Abdollahi A. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation and chemotherapy. Cancer Res. 2005, 65:3643-3655.
75. Yang A.D., Bauer T.W., Camp E.R., Somcio R., Liu W., Fan F., Ellis L.M. Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy. Cancer 2005, 103:1561-1570.
76. Juan T.-J., Roffler S.R., Hou H.-S., Huang S.-M., Chen K.-C., Leu Y.-L., Prijovich Z.M., Yu C.-P., Wu C.-C., Sun G.-H., Cha T.-L. Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumoractivity. Clin. Cancer Res. 2009, 15:4600-4611.
77. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., Chung D.C., Sahani D.V., Kalva S.P., Kozin S.V., Mino M., Cohen K.S., Scadden D.T., Hartford A.C., Fischman A.J., Clark J.W., Ryan D.P., Zhu A.X., Blaszkowsky L.S., Chen H.X., Shellito P.C., Lauwers G.Y., Jain R.K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 2004, 10:145-147.
78. Winkler F., Kozin S.V., Tong R.T., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
79. Lal D., Park J.A., Demock K., Marinaro J., Perez A.M., Lin M.-H., Tian L., Mashtare Y.J., Murphy M., Prey J., Wetzler M., Fetterly G.J., Wang E.S. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models. Mol. Cancer Ther. 2010, 9:2737-2751.
80. Lockhart A.C., Rothenberg M.L., Dupont J., Cooper W., Chevalier P., Sternas L., Buzenet G., Koehler E., Sosman J.A., Schwartz L.H., Gultekin D.H., Koutcher J.A., Donnelly E.F., Andal R., Dancy I., Spriggs D.R., Tew W.P. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J. Clin. Oncol. 2010, 28:207-214.
81. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E.S., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
82. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H. Paclitaxel-carboplatin alone with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355:2542-2550.
83. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349:427-434.
84. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.-T., Duda D.G., Cohen K.S., Kozak K.R., Cahill D.P., Chen P.-J., Zhu M., Ancukiewicz M., Mrugala M.M., Plotkin S., Drappatz J., Louis D.N., Ivy P., Scadden D.T., Benner T., Loeffler J.S., Wen P.Y., Jain R.K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007, 11:83-95.
85. Tailor T.D., Hanna G., Yarmolenko P.S., Dreher M.R., Betof A.S., Nixon A.B., Spasojevic I., Dewhirst M.W. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol. Cancer Ther. 2010, 9:1798-1808.
86. v integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 2010, 70:7591-7599.
87. Escorcia F.E., Henke E., McDevitt M.R., Villa C.H., Smith-Jones P., Blasberg R.G., Benezra R., Scheinberg D.A. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res. 2010, 70:9277-9286.
88. Bhattacharya A., Seshadri M., Oven S.D., Tóth K., Vaughn M.M., Rustum Y.M. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clin. Cancer Res. 2008, 14:3926-3935.
89. Bhattacharya A., Turowski S.G., San Martin I.D., Rajput A., Rustum Y.M., Hoffman R.M., Seshadri M. Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer. Anticancer. Res. 2011, 31:387-393.
90. Hamzah J., Jugold M., Kiessling F., Rigby P., Manzur M., Marti H.H., Rabie T., Kaden S., Gröne H.J., Hämmerling G.J., Arnold B., Ganss R. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, 453:410-415.
91. Liu P., Zhang C., Chen J., Zhang R., Ren J., Huang Y., Zhu F., Li Z., Wu G. Combinational therapy of interferon-α and chemotherapy normalizes tumor vasculature by regulating pericytes including the novel marker RGS5 in melanoma. J. Immunother. 2011, 34:320-326.
92. Jain R.K., Safabakhsh N., Sckell A., Chen Y., Jing P., Benjamin L., Yuan F., Keshet E. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:10820-10825.
93. Viloria-Petit A., Crombet T., Jothy S., Hicklin D., Bohlen P., Schlaeppi J.M., Rak J., Kerbel R.S. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001, 61:5090-5101.
94. Izumi Y., Xu L., di Tomaso E., Fukumura D., Jain R.K. Herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416:279-280.
95. Ansiaux R., Baudelet C., Jordan B.F., Beghein N., Spanveaux P., De Wever J., Martinive P., Brégoire V., Feron O., Gallez B. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin. Cancer Res. 2005, 11:743-750.
96. Keunen O., Johansson M., Oudin A., Sanzey M., Rahim S.A., Fack F., Thorsen F., Taxt T., Bartos M., Jirik R., Miletic H., Wang J., Stieber D., Stuhr L., Moen I., Rygh C.B., Bjerkvig R., Niclou S.P. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:3749-3754.
97. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U.S.A. 1975, 72:3666-3670.
98. Helson L., Green S., Carswell E., Old L.J. Effect of tumour necrosis factor on cultured human melanoma cells. Nature 1975, 258:731-732.
99. Eggermont A.M., Schraffordt Koops H., Liénard D., Kroon B.B., van Geel A.N., Hoekstra H.J., Lejeune F.J. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J. Clin. Oncol. 1996, 14:2653-2665.
100. Eggermont A.M., van Geel A.N., de Wilt J.H., ten Hagen T.L.K. The role of isolated limb perfusion for melanoma confined to the extremities. Surg. Clin. North Am. 2003, 83:371-384. ix.
101. Fraker D.L., Alexander H.R., Andrich M., Rosenberg S.A. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J. Clin. Oncol. 1996, 14:479-489.
102. Lienard D., Ewalenko P., Delmotte J.J., Renard N., Lejeune F.J. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 1992, 10:52-60.
103. Grunhagen D.J., de Wilt J.H., Graveland W.J., van Geel A.N., Eggermont A.M. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer 2006, 106:156-162.
104. Curnis F., Sacchi A., Borgna L., Magni F., Gasparri A., Corti A. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 2000, 18:1185-1190.
105. Curnis F., Arrigoni G., Sacchi A., Fischetti L., Arap W., Pasqualini R., Corti A. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 2002, 62:867-874.
106. Curnis F., Sacchi A., Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest. 2002, 110:475-482.
107. Sacchi A., Gasparri A., Gallo-Stampino C., Toma S., Curnis F., Corti A. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-α. Clin. Cancer Res. 2006, 12:175-182.
108. van Laarhoven H.W., Gambarota G., Heerschap A., Lok J., Verhagen I., Corti A., Toma S., Gallo Stampino C., van der Kogel A., Punt C.J. Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. Invest. New Drugs. 2006, 24:27-36.
109. Gregorc V., Santoro A., Bennicelli E., Punt C.J., Citterio G., Timmer-Bonte J.N., Caligaris Cappio F., Lambiase A., Bordignon C., van Herpen C.M. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br. J. Cancer 2009, 101(2):219-224.
110. Gregorc V., De Braud F.G., De Pas T.M., Scalamogna R., Citterio G., Milani A., Boselli S., Catania C., Donadoni G., Rossoni G., Ghio D., Spitaleri G., Ammannati C., Colombi S., Caligaris-Cappio F., Lambiase A., Bordignon C. Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. Clin. Cancer Res. 2011, 17:1964-1972.
111. Borsi L., Balza E., Carnemolla B., Sassi F., Castellani P., Berndt A., Kosmehl H., Biro A., Siri A., Orecchia P., Grassi J., Neri D., Zardi L. Selective targeted delivery of TNFα to tumor blood vessels. Blood 2003, 102:4384-4392.
112. Balza E., Mortara L., Sassi F., Monteghirfo S., Carnemolla B., Castellani P., Neri D., Accolla R., Zardi L., Borsi L. Targeted delivery of tumor necrosis factor-α to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin. Cancer Res. 2006, 12:2575-2582.
113. Farma J.M., Puhlmann M., Soriano P.A., Cox D., Paciotti G.F., Tamarkin L., Alexander H.R. Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor. Int. J. Cancer 2007, 120:2474-2480.
114. Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., Longhi R., Allen T.M., Corti A., Ponzoni M. Vascular damage and anti-amgiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003, 63:7400-7409.
115. Epstein A.L., Khawli L.A., Hornick J.L., Taylor C.R. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin-2. Cancer Res. 1995, 55:2673-2680.
116. Hornick J.L., Khwali L.A., Hu P., Sharifi J., Khanna C., Epstein A.L. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors. Clin. Cancer Res. 1999, 5:51-60.
117. 2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy. Clin. Cancer Res. 2005, 11:3084-3093.
118. Mårlind J., Kaspar M., Trachsel E., Sommavilla R., Hindle S., Bacci C., Giovannoni L., Neri D. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin. Cancer Res. 2008, 14:6515-6524.
119. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., Hanahan D., Mattrey R.F., Ruoslahti E. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 2009, 16:510-520.
120. Brunstein F., Rens J., Eggermont A.M.M., ten Hagen T.L.M. Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery. Br. J. Cancer 2006, 95:1663-1669.
121. Yin D., Konda B.M., Ong J.M., Hu J., Sacapano M.R., Koo M.H.K., Espinoza A.J., Irvin D.K., Shu Y., Black K.L. Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors. Clin. Cancer Res. 2008, 14:4002-4009.
122. Zhou R., Mazurchuk R., Straubinger R.M. Antivascular effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res. 2001, 62:2561-2566.
123. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010, 52:762-773.
124. Nilsson F., Kosmehl H., Zardi L., Neri D. Targeted delivery of tissue factor to the ED-B domain of firbonectin, a marker of angiogenesis, mediates infarction of solid tumors in mice. Cancer Res. 2001, 61:711-716.
125. Hu P., Yan J., Sharifi J., Bai T., Khawli L.A., Epstein A.L. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res. 2003, 63:5046-5053.
126. Dienst A., Grunow A., Unruh M., Rabausch B., Nor J.E., Fries J.W., Gottstein C. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J. Natl. Cancer Inst. 2005, 97:733-747.
127. Madar-Balakirski N., Tempel-Brami C., Kalchenko V., Brenner O., Varon D., Scherz A., Salomon Y. Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad. PLoS One 2010, 5:e10282.
128. Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., Sasisekharan R. Temporal targeting of tumor cells and neovasculature with a nanoscale delivery system. Nature 2005, 436:568-572.
129. McKeage M.J., Baguley B.C. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 2010, 116:1859-1871.
130. Strieth S., Eichhorn M.E., Werner A., Sauer B., Teifel M., Michaelis U., Berghaus A., Dellian M. Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with cisplatin. Clin. Cancer Res. 2008, 14:4601-4603.
131. Zhao L., Ching L.M., Kestell P., Kelland L.R., Baguley B.C. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): increased tumor vascular permeability. Int. J. Cancer 2005, 116:322-326.
132. Strieth S., Nussbaum C.F., Eichhorn M.E., Fuhrmann M., Teifels M., Michaelis U., Berghaus A., Dellian M. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int. J. Cancer 2008, 122(2008):452-460.
133. Eichhorn M.E., Ischenko I., Luedemann S., Strieth S., Papyan A., Werner A., Bohnenkamp H., Guenzi E., Preissler G., Michaelis U., Jauch K.-W., Bruns C.-J., Dellian M. Vascular targeting by EndoTAG™-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int. J. Cancer 2010, 126:1235-1245.
134. Pruijn F.B., van Daalen M., Holford N.H., Wilson W.R. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour blood-flow inhibitor 5, 6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 1997, 39:541-546.
135. Siim B.G., Lee A.E., Shalal-Zwain S., Pruijn F.B., McKeage M.J., Wilson W.R. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5, 6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother. Pharmacol. 2003, 51:43-52.
136. Pedley R.B., Boden J.A., Boden R., Boxer G.M., Flynn A.A., Keep P.A., Begent R.H. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res. 1996, 56:3293-3300.
137. Pedley R.B., Sharma S.K., Boxer G.M., Boden R., Stribbling S.M., Davies L., Springer C.J., Begent R.H. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res. 1999, 59:3998-4003.
138. Skliarenko J.V., Lunt S.J., Gordon M.L., Vitkin A., Milosevic M., Hill R.P. Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. Cancer Res. 2006, 66:2074-2080.
139. Morinaga Y., Suga Y., Ehara S., Harada K., Nihei Y., Suzuki M. Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci. 2003, 94:200-204.
140. McIntosh D.P., Tan X.Y., Oh P., Schnitzer J.E. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:1996-2001.
141. Huang S.K., Martin F.J., Jay G., Vogel J., Papahadjopoulos D., Friend D.S. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am. J. Pathol. 1993, 143:10-14.
142. Staquicini F.I., Ozawa M.G., Moya C.A., Driessen W.H.P., Barbu E.M., Nishimori H., Soghomonyan S., Flores L.G., Liang X., Paolillo V., Alauddin M.M., Basilion J.P., Furnari F.B., Bogler O., Lang F.F., Aldape K.D., Fuller G.N., Höök M., Gelovani J.G., Sidman R.L., Cavenee W.K., Pasqualini R., Arap W. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J. Clin. Invest. 2011, 121:161-173.
143. Griffon-Etienne G., Boucher Y., Brekken C., Suit H.D., Jain R.K. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors. Cancer Res. 1999, 59:3776-3782.
144. Taghian A.G., Abi-Raad R., Assaad S.I., Casty A., Ancukiewicz M., Yeh E., Molokhia P., Attia A., Sullivan T., Kuter I., Boucher Y., Powell S.N. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancer patients treated with neoadjuvant chemotherapy: clinical implications. J. Clin. Oncol. 2005, 23:1951-1961.
145. 111In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?. Clin. Cancer Res. 2005, 11:7158s-7163s.
146. y humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clin. Cancer Res. 2000, 6:3621-3628.
147. DeNardo S.J., Kukis D.L., Kroger L.A., O'Donnell R.T., Lamborn K.R., Miers L.A., DeNardo D.G., Meares C.F., DeNardo G.L. Synergy of taxol and radioimmunotherapy with yttrium-90-labeles chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:4000-4004.
148. Holden S.A., Lan Y., Pardo A.M., Wesolowski J.S., Gillies S.D. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents (EMD 273066). Clin. Cancer Res. 2001, 7:2862-2869.
149. Eikenes L., Bruland Ø.S., Brekken C., de Lange Davies C. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human sarcoma xenografts. Cancer Res. 2004, 64:4768-4773.
150. Brekken C., de Lange Davies C. Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Cancer Lett. 1998, 131:65-70.
151. Brekken C., Bruland Ø.S., De Lange Davis C. Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase. Anticancer. Res. 2000, 20:3503-3512.
152. Brekken C., Hjelstuen M.H., Bruland Ø.S., De Lange Davis C. Hyaluronidase-induced periodic modulation fo the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts. Anticancer. Res. 2000, 20:3513-3520.
153. Eikenes L., Tari M., Tufto I., Bruland Ø.S., de Lange Davies C. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br. J. Cancer 2005, 93:81-88.
154. Diop-Frimpong B., Chauhan V.P., Krane S., Boucher Y., Jain R.K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:2909-2914.
155. Rubin K., Sjöquist M., Gustafsson A.-M., Isaksson B., Salvessen G., Reed R.K. Lowering of tumoral interstitial fluid pressure by prostaglandin E1 is paralleled by an increased uptake of 51Cr-EDTA. Int. J. Cancer 2000, 86:636-643.
156. Salnikov A.V., Iversen V.V., Koisti M., Sundberg C., Johansson L., Stuhr L.B., Sjöquist M., Ahlström H., Reed R.K., Rubin K. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J. 2003, 17:1756-1758.
157. Rodt S.A., Ahlén K., Berg A., Rubin K., Reed R.K. A novel physiological function for platelet-derived growth factor-BB in rat dermis. J. Physiol. 1996, 495:193-200.
158. Pietras K., Östman A., Sjöquist M., Buchdunger E., Reed R.K., Heldin C.-H., Rubin K. Inhibition of platelet-derived growth factor receptors reduces intestitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001, 61:2929-2934.
159. Pietras K., Rubin K., Sjöblom T., Buchdunger E., Sjöquist M., Heldin C.-H., Östman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002, 62:5476-5484.
160. Baranowska-Kortylewicz J., Abe M., Nearman J., Enke C.A. Emerging role of platelet-derived growth factor receptor-B inhibition in radioimmunotherpay of experimental pancreatic cancer. Clin. Cancer Res. 2007, 13:299-306.
161. Baranowska-Kortylewicz J., Abe M., Pietras K., Kortylewicz Z.P., Kurizaki T., Nearman J., Paulsson J., Mosley R.L., Enke C.A., Östman A. Effect of platelet-derived growth factor receptor-β inhibition with STI571 on radioimmunotherapy. Cancer Res. 2005, 65:7824-7831.
162. Pietras K., Stumm M., Hubert M., Buchdunger E., Rubin K., Heldin C.-H., McSheehy P., Wartmann M., Östman A. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin. Cancer Res. 2003, 9:3779-3787.
163. Roberts W.G., Whalen P.M., Soderstrom E., Moraski G., Lyssikatos J.P., Wang H.-F., Cooper B., Baker D.A., Savage D., Dalvie D., Atherton J.A., Ralston S., Szwec R., Kath J.C., Lin J., Soderstrom C., Tkalcevic G., Cohen B.D., Pollack V., Barth W., Hungerford W., Ung E. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res. 2005, 65:957-966.
164. Jayson G.C., Parker G.J.M., Mullamitha S., Valle J.W., Saunders M., Broughton L., Lawrance J., Carrington B., Roberts C., Issa B., Buckley D.L., Cheung S., Davies K., Watson Y., Zinkewich-Péotti K., Rolfe L., Jackso A. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J. Clin. Oncol. 2005, 23:973-981.
165. Lammerts E., Roswall P., Sundberg C., Gotwals P.J., Kotliansky V.E., Reed R.K., Heldin C.-H., Rubin K. Interference with TGF-β1 and -β3 in tumor stroma lowers tumor intersitial fluid pressure independently of growth in experimental carcinoma. Int. J. Cancer 2002, 102:453-462.
166. Jacobson A., Salnikov A., Lammerts E., Roswall P., Sundberg C., Heldin P., Rubin K., Heldin N.E. Hyaluronan content in experimental carcinoma is not correlated to interstitial fluid pressure. Biochem. Biophys. Res. Commun. 2003, 305:1017-1023.
167. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., Frese K.K., DeNicola G., Feig C., Combs C., Winter S.P., Ireland H., Reichelt S., Howat W.J., Chang A., Dhara M., Wang L., Rückert F., Grützmann R., Pilarsky C., Izeradjene K., Hingorani S.R., Huang P., Davies S.E., Plunkett W., Egorin M., Hruban R.H., Whitebread N., McGovern K., Adams J., Iacobuzio-Donahue C., Griffiths J., Tuveson D.A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
168. Willett C.G., Boucher Y., Duda D.G., di Tomaso E., Munn L.L., Tong R.T., Kozin S.V., Petit L., Jain R.K., Chung D.C., Sahani D.V., Kalva S.P., Cohen K.S., Scadden D.T., Fischman A.J., Clark J.W., Ryan D.P., Zhu A.X., Blaszkowsky L.S., Shellito P.C., Mino-Kenudson M., Lauwers G.Y. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol. 2005, 23:8136-8139.
169. Xu L., Duda D.G., di Tomaso E., Ancukiewicz M., Chung D.C., Lauwers G.Y., Samuel R., Shellito P., Czito B.G., Lin P.-C., Poleski M., Bentley R., Clark J.W., Willett C.G., Jain R.K. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1α, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 2009, 69:7905-7910.
170. Morgan B., Thomas A.L., Drevs J., Hennig J., Buchert M., Jivan A., Horsfield M.A., Mross K., Ball H.A., Lee L., Mietlowski W., Fuxuis S., Unger C., O'Byrne K., Henry A., Cherryman G.R., Laurent D., Dugan M., Marmé D., Steward W.P. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 2003, 21:3955-3964.
171. Tai J.H., Tessier J., Ryan A.J., Hoffman L., Chen X., Lee T.-Y. Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat. Neoplasia 2010, 12:697-707.
172. Bergers B., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
173. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
174. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.